增强凝血因子VIII激活可加速凝血酶生成并提升小鼠止血效力
研究通过构建仅需Arg372切割即可活化的FVIII变体(FVIII-2RKR),发现其血浆表观活性增强、凝血酶生成滞后期缩短、FXa生成增加,且比B结构域缺失FVIII更易被凝血酶和FXa切割;在血友病A小鼠中低剂量即增强早期止血功能,vWF缺陷小鼠中仍有效。
要点
- FVIII-2RKR仅需Arg372切割即可活化,表观活性明显高于BDD-FVIII。
- 在血友病A小鼠中FVIII-2RKR低剂量即增强早期止血功能。
- vWF结合受损致半衰期缩短,但局部止血功能不依赖vWF。
核心结论
- FVIII的Arg740和Arg1689切割通过调节Arg372切割速率来调控激活,激活速率与体内止血效力相关。
研究设计与样本
- 工程化FVIII变体(FVIII-2RKR)体外功能比较及血友病A小鼠和vWF缺陷小鼠体内止血模型研究。
主要发现
- FVIII-2RKR在血浆试验中表观活性明显增加,凝血酶生成滞后期缩短,FXa生成增强。
- FVIII-2RKR被凝血酶和FXa切割Arg372更快;凝血酶激活后与BDD-FVIII功能等效。
- 在氯化铁、激光损伤和尾部出血模型中,FVIII-2RKR低剂量即增强早期止血功能。
- FVIII-2RKR因vWF结合受损致半衰期缩短,但在vWF缺陷小鼠中仍有效。
临床怎么用
- 提示增强FVIII激活速率可能以更低剂量提升止血效力,vWF非局部止血所必需。
局限性
- 原文未报告具体样本量、剂量、P值等数值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Factor VIII (FVIII) circulates as an inactive procofactor and is converted to its active form (FVIIIa) by proteolytic cleavage at Arg372, Arg740, and Arg1689. Although these cleavage events are well characterized, their individual contributions to FVIII activation and hemostatic function remain incompletely defined. To address this, we engineered a FVIII variant (FVIII-2RKR) in which the B-domain and acidic region 3 region were replaced with a PACE/furin processing site, generating a molecule that requires only cleavage at Arg372 for conversion to FVIIIa. FVIII-2RKR exhibited markedly increased apparent activity in plasma-based assays, shortened thrombin generation lag time, and enhanced factor Xa (FXa) generation compared with B-domain-deleted FVIII, whereas both proteins were functionally equivalent following thrombin activation. FVIII-2RKR was cleaved more rapidly at Arg372 by thrombin and FXa, demonstrating that processing at Arg740 and Arg1689 regulates the rate of Arg372 cleavage rather than directly contributing to cofactor activity. In hemophilia A mice, FVIII-2RKR consistently enhanced early hemostatic function across ferric chloride, laser injury, and tail bleeding models, achieving improved efficacy at lower doses. Despite reduced half-life due to impaired von Willebrand factor (vWF) binding, FVIII-2RKR remained effective in vWF-deficient mice, indicating that vWF is not required for local FVIII function at sites of vascular injury. Together, these findings define distinct roles for FVIII activation cleavage sites and demonstrate that processing at Arg740 and Arg1689 regulates activation through Arg372, linking the rate of FVIII activation to hemostatic efficacy in vivo.
引用
- Ivanciu L, Bos MHA, Parthasarathy S, et al. Enhanced factor VIII activation accelerates thrombin generation and hemostatic potency in mice. Blood. 2026. PMID: 42821745. doi:10.1182/blood.2026034984
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。